Search results for "Reaction"

showing 10 items of 6134 documents

Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study).

2007

Background: Trastuzumab is widely used as the treatment of choice for HER2-positive metastatic breast cancer (MBC). Patients and methods: Seventy patients, median age 57 years and range 31-81 years, were included in our retrospective analysis with the aim to evaluate safety and activity of trastuzumab-containing therapies. Results: We observed for first-line treatment response rate (RR) 41%, stable disease (SD) 47% and time to progression (TTP) 8 months (range 1-44). Corresponding numbers for second line were RR 23%, SD 62% and (TTP) 9 months (range 3-23) and beyond second line RR 22%, SD 78% and (TTP) 9 months (range 4-19). Overall survival was 19.2 months (3-62 months). The median cumulat…

OncologyAdultmedicine.medical_specialtyDrug-Related Side Effects and Adverse Reactionscardiac safety clinical experience heavily pretreated women metastatic breast cancer retrospective analysis trastuzumabAntineoplastic AgentsBone NeoplasmsBreast NeoplasmsSoft Tissue NeoplasmsAntibodies Monoclonal HumanizedAsymptomaticMetastasisBreast cancerTrastuzumabcardiac safety; clinical experience; heavily pretreated women; metastatic breast cancer; retrospective analysis; trastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansskin and connective tissue diseasesAdverse effectneoplasmsAgedRetrospective StudiesAged 80 and overEjection fractionbusiness.industryCumulative doseAntibodies MonoclonalHematologyMiddle AgedTrastuzumabmedicine.diseaseMetastatic breast cancerSurgeryTreatment OutcomeOncologyFemalemedicine.symptombusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Human papillomavirus (HPV) DNA in primary cervical cancer and in cancer free pelvic lymph nodes--correlation with clinico-pathological parameters and…

2001

OBJECTIVE To assess whether the presence of human papilloma virus (HPV) DNA and/or several genotypes of HPV DNA in primary cervical cancer and cancer free pelvic lymph nodes are correlated with several clinicopathological parameters of well-defined prognostic significance and whether virological parameters are predictors of long-term survival in cancer patients. PATIENTS AND METHODS 223 cases of cervical cancer patients included in this retrospective study underwent follow-up evaluation. Survival and cause of death were examined for 204 (91.4%) patients, with a mean follow-up time of 4.4 years. HPV DNA was detected using the high sensitive polymerase chain reaction (PCR) method followed by …

OncologyAdultmedicine.medical_specialtyGenotypeUterine Cervical NeoplasmsAdenocarcinomaPolymerase Chain Reactionlaw.inventionCarcinoma AdenosquamouslawInternal medicineGenotypeMedicineHumansNeoplasm InvasivenessLymph nodePapillomaviridaePolymerase chain reactionAgedRetrospective StudiesCervical cancerAged 80 and overbusiness.industryPapillomavirus InfectionsObstetrics and GynecologyCancerMiddle Agedmedicine.diseasePrognosisPrimary tumorSurvival AnalysisKoilocyteTumor Virus Infectionsmedicine.anatomical_structureLymphatic MetastasisDNA ViralCarcinoma Squamous CellFemaleLymphLymph NodesbusinessFollow-Up StudiesZentralblatt fur Gynakologie
researchProduct

The presence of HPV DNA in cervical cancer: correlation with clinico-pathologic parameters and prognostic significance: 10 years experience at the De…

2001

The objective of this study was to assess whether the presence of human papillomavirus (HPV) DNA and/or several genotypes of HPV DNA in cervical cancer are correlated with several clinicopathologic parameters of well-defined prognostic significance and whether virologic parameters are predictors of long-term survival in cancer patients. Two hundred twenty three cases of cervical cancer patients included in this retrospective study underwent follow-up evaluation. Survival and cause of death were examined for 204 (91.4%) patients, with a mean follow-up time of 4.4 years. HPV DNA was detected using the highly sensitive polymerase chain reaction (PCR) method followed by HPV DNA sequencing for H…

OncologyAdultmedicine.medical_specialtyGenotypeUterine Cervical NeoplasmsAdenocarcinomaPolymerase Chain Reactionlaw.inventionCarcinoma AdenosquamouslawInternal medicineGenotypemedicineCarcinomaHumansPapillomaviridaePapillomaviridaeSurvival analysisPolymerase chain reactionAgedRetrospective StudiesGynecologyCervical cancerAged 80 and overbiologybusiness.industryPapillomavirus Infectionsvirus diseasesObstetrics and GynecologyCancerMiddle Agedmedicine.diseasebiology.organism_classificationPrognosisSurvival Analysisfemale genital diseases and pregnancy complicationsTumor Virus InfectionsOncologyDNA ViralCarcinoma Squamous CellAdenocarcinomaFemalebusinessInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
researchProduct

Distribution of human papillomavirus types in women from Valencia, Spain, with abnormal cytology.

2010

Objective To determine human papillomavirus (HPV) types among cervical smears using polymerase chain reaction (PCR) and to contribute to the knowledge of human papillomavirus genotype distribution and prevalence of oncogenic types in cervical lesions in Spain. Study Design Consensus PCR and direct sequencing of PCR products (DNA HPV typing) were used in a retrospective study to determinate the type or types of HPV on 974 cytology smears of women with abnormal cytology results. Results Of 974 smears, 79.8% were high-risk (H-R) HPVs, 19.7% low-risk (L-R) HPVs, 4.6% indeterminate-risk (I-R) HPVs, considering both single and multiple infections. Multiple infections were detected in 4.7% of the …

OncologyAdultmedicine.medical_specialtyHistologyGenotypeCost effectivenessPopulationPrevalenceUterine Cervical NeoplasmsAlphapapillomavirusCervical intraepithelial neoplasiaPolymerase Chain ReactionPathology and Forensic MedicineGene FrequencyCytologyInternal medicineGenotypemedicinePrevalenceHumansMass ScreeningeducationMass screeningRetrospective StudiesGynecologyVaginal Smearseducation.field_of_studyHuman papillomavirus 16Human papillomavirus 18business.industryPapillomavirus Infectionsvirus diseasesGeneral Medicinemedicine.diseaseUterine Cervical Dysplasiafemale genital diseases and pregnancy complicationsSquamous intraepithelial lesionSpainDNA ViralFemalebusinessActa cytologica
researchProduct

Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary resu…

2006

BACKGROUND: Mammaglobin is expressed mainly in mammary tissue, overexpressed in breast cancer (BC) and rarely in other tissue. The aim of this study was to assess the sensitivity and specificity of transcript MGB1 detection and to evaluate the role of MGB1 as potential clinical marker for the detection of disseminated cancer cells in the blood of BC patients. PATIENTS AND METHODS: A consecutive series of 23 BC tissues, 36 peripheral blood BC samples and 35 healthy peripheral blood samples was prospectively recruited to investigate MGB1 expression by means of a quantitative Real Time RT-PCR assay. RESULTS: MGB1 overexpression in tissue samples of BC patients is significantly associated only …

OncologyAdultmedicine.medical_specialtyPathologySettore MED/06 - Oncologia MedicaMrna expressionClinical markerBreast NeoplasmsSensitivity and SpecificityMammaglobinBreast cancerInternal medicinemedicineBiomarkers TumorHumansUteroglobinProspective StudiesRNA MessengerProspective cohort studyAgedAged 80 and overbiologybusiness.industryReverse Transcriptase Polymerase Chain ReactionMammaglobin AMammary tissuemammaglobyn brest cancerHematologyMiddle Agedmedicine.diseaseNeoplastic Cells CirculatingPeripheral bloodNeoplasm ProteinsOncologybiology.proteinFemalebusinessDisseminated cancer
researchProduct

Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer

2020

BACKGROUND: Colon cancer (CC) is a heterogeneous disease. Novel prognostic factors beyond pathological staging are required to accurately identify patients at higher risk of relapse. Integrating these new biological factors, such as plasma circulating tumour DNA (ctDNA), CDX2 staining, inflammation-associated cytokines and transcriptomic consensus molecular subtypes (CMS) classification, into a multimodal approach may improve our accuracy in determining risk of recurrence.; METHODS: One hundred and fifty patients consecutively diagnosed with localised CC were prospectively enrolled in our study. ctDNA was tracked to detect minimal residual disease by droplet digital PCR. CDX2 expression was…

OncologyCancer Researchmedicine.medical_specialtyColorectal cancerPathological stagingConsensus molecular subtypesPerineural invasionlcsh:RC254-282Circulating Tumor DNAInternal medicinemedicineBiomarkers TumorHumansDigital polymerase chain reactionCDX2 Transcription Factor1506plasma circulating-tumor DNAStage (cooking)Original Researchbusiness.industryInterleukin-6Plasma circulating-tumor DNA.Multimodal therapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisMinimal residual diseaseColon cancerOncologyColonic NeoplasmsCDX2 homeoprotein; colon cancer; consensus molecular subtypes; interleukin-6; plasma circulating-tumor DNANeoplasm Recurrence LocalbusinessCDX2 homeoproteinImmunostaining
researchProduct

Autologous Transplantation of In Vivo Purged PBSC in CML

2000

To determine the effectiveness of different methods for the detection of tumor cell contamination of collected peripheral stem cells, we performed a study on 39 chronic myelogenous leukemia (CML) patients who were consecutively treated at our department. Analyses of tumor cell contamination by fluorescence in situ hybridization (FISH), conventional cytogenetics, and polymerase chain reaction (PCR) showed marked differences in the percentage of evaluable results: Quantitative analysis of tumor cell contamination was feasible in 60 of 105 (57%) samples evaluated with the use of conventional cytogenetic analysis and in 105 of 107 (98%) samples analyzed by FISH. PCR was evaluable in all 85 samp…

OncologyCancer Researchmedicine.medical_specialtymedicine.diagnostic_testCytogeneticsLeukapheresisBiologymedicine.diseasePhiladelphia chromosomelaw.inventionlawInternal medicineImmunologyGeneticsmedicineAutologous transplantationStem cellMolecular BiologyPolymerase chain reactionChronic myelogenous leukemiaFluorescence in situ hybridizationCancer Genetics and Cytogenetics
researchProduct

Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer

2013

Use of anti-epidermal growth factor receptor (anti-EGFR) agents has yielded significant advances in the treatment of patients with metastatic colorectal cancer. In fact these drugs, which include the monoclonal antibodies cetuximab and panitumumab, can be delivered both as a single agent and in combination with chemotherapy, achieving better survival and quality of life and in some cases also resectability of metastases. However, these agents can result in the development of toxicities that are usually different from those observed with chemotherapy alone. For the management of these adverse effects, proper knowledge is mandatory. Skin toxicity is the most frequent adverse effect. Other tox…

OncologyColorectal cancerSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPulmonary FibrosisCetuximabPharmacologyPrurituMagnesiumEpidermal growth factor receptorParonychiaCancerSkinbiologyCetuximabPanitumumabGastroenterologyfood and beveragesCutaneouOncologyToxicityMetastaticmedicine.drugDiarrheamedicine.medical_specialtyGastrointestinalAnti-epidermal growth factor receptorColonReactionInternal medicineRashmedicinePanitumumabToxicity; Epidermal growth factor receptor; Anti-epidermal growth factor receptor; Cetuximab; Panitumumab; Antibody; Metastatic; Colon; Rectum; Cancer; Treatment; Skin; Rash; Cutaneous; Pruritus; Xerosis; Paronychia; Hypomagnesemia; Magnesium; Gastrointestinal; Diarrhea; Infusion; Reaction; Pulmonary FibrosisInfusionAdverse effectAntibodyXerosisChemotherapyHepatologyToxicitybusiness.industryEpidermal growth factor receptorPruritusRectumCancermedicine.diseaseXerosiTreatmentCutaneousbiology.proteinHypomagnesemiabusiness
researchProduct

Association of candidate pharmacogenetic markers with platinum-induced ototoxicity

2020

Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (TPMT) is considered a critical gene for susceptibility to cisplatin-induced hearing loss in a pharmacogenetic guideline. The PanCareLIFE cross-sectional cohort study evaluated the genetic associations in a large pan-European population and assessed the diagnostic accuracy of the genetic markers. 1,112 pediatric cancer survivors who had provided biomaterial for genotyping were screened for participation in the pharmacogenetic association study. 900 participants qualified for inclusion. Based on the assessment of original audiograms, patien…

OncologyDrug-induced ototoxicitymedicine.medical_specialtyCandidate geneHearing lossMulticenter cohort studyCancer survivorsPopulationAdverse drug reaction610 Medicine & healthlcsh:Computer applications to medicine. Medical informatics03 medical and health sciences0302 clinical medicine360 Social problems & social servicesInternal medicinemedicineGenetic predisposition610 Medicine & healtheducationlcsh:Science (General)030304 developmental biologyGenetic association0303 health scienceseducation.field_of_studyMultidisciplinaryThiopurine methyltransferasebiologycarboplatin [Cisplatin]business.industryMedicine and DentistryPediatric cancerCisplatin: carboplatinPharmacogeneticsbiology.proteinlcsh:R858-859.7Genetic markersmedicine.symptombusinessChildhood cancer360 Social problems & social services030217 neurology & neurosurgeryPharmacogeneticslcsh:Q1-390Data in brief
researchProduct

Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensu…

2012

Abstract Background Recent emerging evidences identify Human Papillomavirus (HPV) related Head and Neck squamous cell carcinomas (HN-SCCs) as a separate subgroup among Head and Neck Cancers with different epidemiology, histopathological characteristics, therapeutic response to chemo-radiation treatment and clinical outcome. However, there is not a worldwide consensus on the methods to be used in clinical practice. The endpoint of this study was to demonstrate the reliability of a triple method which combines evaluation of: 1. p16 protein expression by immunohistochemistry (p16-IHC); 2. HPV-DNA genotyping by consensus HPV-DNA PCR methods (Consensus PCR); and 3 viral integration into the host…

OncologyHuman papillomavirusHPVCancer Researchmedicine.medical_specialtyPathologyMethylation-Specific PCREpidemiologySettore MED/50 - Scienze Tecniche Mediche ApplicateBisulfite sequencingConsensus PCRIn situ hybridizationSettore MED/08 - Anatomia Patologicalcsh:RC254-282lcsh:Infectious and parasitic diseasesHPV-DNA; in situ hybridationSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineDNA consensus PCRlcsh:RC109-216p16-IHCin situ hybridationGenotypingHN-SCCOPSCCbusiness.industryHead and neck cancerEpigeneticHPV-DNAHead and neck squamous cell carcinomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmunohistochemistryHead and neck squamous-cell carcinomastomatognathic diseasesInfectious DiseasesReal-time polymerase chain reactionOncologyImmunohistochemistryOSCCbusinessResearch ArticleIHCInfectious Agents and Cancer
researchProduct